• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Bicycle Therapeutics plc

    < Previous 1 2 Next >
    Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Enhances Leadership Team with Key Appointments
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in Upcoming Investor Conferences
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in Upcoming Investor Conferences
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
    From Bicycle Therapeutics plc
    Via Business Wire
    Tickers BCYC
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.